Videos

Real-world data from the FARETINA-AMD study show faricimab extended treatment intervals among eyes with nAMD.

This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.

Safer discusses how symptoms and quality of life often go unaddressed in the few clinician-patient interactions about primary sclerosing cholangitis.

Lassailly discusses the role of bariatric surgery versus weight-loss treatments like semaglutide for patients with MASH.

During this interview segment, Dr. Chovatiya further analyzed the updated National Psoriasis Foundation consensus statements for GPP and the future of treatment research.

At AAO 2023, Korobelnik provides insight into the efficacy and safety of aflibercept 8 mg in patients with nAMD observed over 2 years of the PULSAR study.

During this segment of his interview, Dr. Kim went into the Harmony study data on safety of ADP101 presented at ACAAI as well as the implications of the research.

In this interview segment, Dr. Kim described some of the background and importance of the Harmony study data presented at ACAAI for patients with food allergy.

Presented at AHA 2023, new analyses of VOYAGER PAD suggest the benefit of rivaroxaban plus aspirin for high-risk and complex populations with PAD.

Sanyal discusses the makeup of retatrutide and its potential for patients with fatty liver disease and comorbid metabolic conditions.

Veeral Sheth, MD, MBA discusses the 3 improvements needed for the future of treating patients with geographic atrophy.

Veeral Sheth, MD, MBA discusses safety signals reported with the use of approved therapies for geographic atrophy and the importance of real-world datasets.

Veeral Sheth, MD, MBA, discusses how clinicians are beginning to use these therapies and the patient reaction to the availability of treatments for GA.

Veeral Sheth, MD, MBA, discusses the clinical trial data that led to FDA approval of SYFOVRE and IZERVAY for geographic atrophy.

Veeral Sheth, MD discusses the two newly FDA-approved therapies for geographic atrophy: pegcetacoplan injection (SYFOVRE) and avacincaptad pegol (IZERVAY).

Veeral Sheth, MD, MBA describes the presentation of geographic atrophy in patients and how they are first affected by the disease.

David Lally, MD describes the hallmark features of geographic atrophy and how the disease develops over time.

This interview segment with Dr. Fakih featured a discussion about his team’s findings and their methodology on the topic of spondyloarthritis.

This discussion with Dr. Hunter covered the takeaways from his team’s phase 3 findings on treatment of osteoarthritis of the knee.

During this interview segment, Dr. Alevizos discussed some of the implications of his team’s findings regarding dazodalibep.

In this interview, Dr. Alevizos described the major takeaways from his team’s findings on this drug for Sjögren's Syndrome.

Findings from The Liver Meeting show the impact of acute alcoholic hepatitis on progression to severe disease and risk of death among younger populations.

As more cases continue to disproportionately affect US women, an expert explains the biologic, sociocultural and clinical factors impacting the climb.

A trio of investigators discuss how research into bile acid interplay with the gut may lead to breakthroughs in treating conditions like NAFLD and NASH.

A trio of scientists discuss the inception of a daylong Liver Meeting symposium around a little-understood subject in hepatic disease.

Presented at AAO 2023, new data show dual Ang-2/VEGF-A inhibition with faricimab improved pigment epithelial detachment outcomes versus aflibercept.

In a pooled subcohort analysis of YOSEMITE and RHINE, faricimab showed comparable vision outcomes with fewer injections than aflibercept in DME eyes with baseline BCVA of ≤ 20/50.

Patients who are female, in minority groups (particularly, Black or Asian), a visual acuity outside of the <20/40 to 20/200 range, and who are >70 years old receive less treatment.

In this segment of his interview, Dr. Chovatiya discussed some of the key safety data on secukinumab following the drug’s FDA approval for hidradenitis suppurativa.

In this interview, Dr. Chovatiya responds to questions about the new FDA approval of secukinumab for patients with hidradenitis suppurativa.